If you work in primary care, pediatrics, or adolescent medicine, you have probably noticed something over the past few years: more teens and young adults coming in with unexplained nausea, heartburn, or stomach pain. Maybe you have worked them up and found nothing structural. Maybe they have been diagnosed with functional dyspepsia or early-onset GERD and put on a PPI. And maybe nobody asked, specifically, whether they use nicotine pouches. If you are a parent, you might be in a similar position. Your teen is complaining about stomach problems, and you are trying to figure out why. Nicotine pouches are worth considering, because their use in this age group is rising fast and their GI effects are real.
How common is nicotine pouch use among teens and young adults?
The numbers are moving quickly. Zyn, the dominant nicotine pouch brand in the U.S., reported shipping 385 million cans in 2024, up from roughly 90 million in 2022 (Philip Morris International earnings reports). While the company markets exclusively to adults, sales data from Nielsen and market research firms show that the fastest-growing consumer segment is 18-to-24-year-olds.
For minors, the data is harder to pin down because pouches are relatively new to national surveillance tools. The 2023 National Youth Tobacco Survey (NYTS) from the CDC and FDA found that approximately 1.5% of high school students reported using oral nicotine products (a category that includes pouches), representing roughly 230,000 students. That number is likely an undercount, because survey-based prevalence relies on honest self-reporting, and many teens may not classify pouches as a 'tobacco product' in their minds.
The 2024 Monitoring the Future survey from the University of Michigan found that nicotine pouch awareness among 12th graders reached 72%, with past-30-day use at roughly 8% among males in that cohort. These products have moved from niche to mainstream among young people in a remarkably short time.
âšī¸Nicotine pouches are marketed as tobacco-free, discrete, and spit-free. These attributes make them particularly appealing to young users, who can use them in class, at work, or at home without visible signs. This same discretion makes them invisible to parents and clinicians who are not asking about them specifically.
What GI symptoms do nicotine pouches cause in young users?
The GI effects of nicotine are not age-specific in their mechanism, but they may present differently in young users because of patterns of use and because the developing GI system may respond differently. Based on the pharmacology of nicotine and clinical observations, the following symptoms are the most relevant.
Nausea is the most commonly reported GI complaint among nicotine pouch users across all ages, and it is likely more prevalent among newer, younger users who are titrating their own dose without guidance. A nicotine-naive 16-year-old using a 6 mg pouch for the first time will absorb nicotine into a system that has no tolerance. The nicotinic receptors in the chemoreceptor trigger zone (the brain's nausea center) are activated, producing nausea that can be intense. Experienced users develop tolerance to this effect, but early use often involves repeated nausea episodes.
Heartburn and acid reflux result from nicotine's relaxation of the lower esophageal sphincter (LES). A 2021 meta-analysis by Ness-Jensen et al. in the American Journal of Gastroenterology confirmed that nicotine exposure is an independent risk factor for GERD symptoms. In young users without other GERD risk factors, nicotine pouch use should be on the differential when heartburn develops.
Epigastric pain (upper abdominal discomfort) can result from nicotine's stimulation of gastric acid secretion combined with the alkaline buffering agents in pouch saliva reaching the stomach. This can mimic functional dyspepsia or peptic-type symptoms.
Changes in bowel habits, including increased frequency or urgency, reflect nicotine's effect on gut motility. Nicotine stimulates colonic contractions through nicotinic acetylcholine receptors in the enteric nervous system (Kadowaki et al., Journal of Pharmacology and Experimental Therapeutics, 1996). Young users may notice this as needing to use the bathroom shortly after placing a pouch.
Hiccups are frequently reported, especially when users swallow saliva with dissolved nicotine. This is a shared effect with nicotine gum and likely involves vagal or phrenic nerve irritation.
Why do teens not connect their stomach problems to nicotine pouches?
Several factors converge here. First, the marketing and social media discourse around nicotine pouches emphasizes what they are not: no tobacco, no smoke, no spit, no smell. In the mental model of most young users, pouches are categorically different from cigarettes. If pouches are not 'bad' in the way cigarettes are, it does not occur to users that they could be causing physical symptoms.
Second, the time delay between pouch use and some GI symptoms obscures the connection. Nausea may appear within minutes (easy to connect), but heartburn may develop hours later or build gradually with cumulative use over days. Changes in bowel habits develop over weeks. These slower-onset symptoms do not scream 'this is from your pouches' the way immediate nausea does.
Third, teens and young adults often use multiple products that can cause GI symptoms: energy drinks (high caffeine, acidic), alcohol, high-fat fast food, and sometimes other substances. When GI symptoms develop, it is easy (and sometimes partially correct) to attribute them to these other exposures. Nicotine pouches get lost in the noise.
Finally, there is the disclosure problem. Teens may not mention pouch use to a doctor because they do not want their parents to find out, because they do not think it is medically relevant, or because the clinician did not ask. If the intake form asks 'Do you smoke?' or 'Do you vape?' and the answer to both is no, pouch use goes unmentioned.
What should primary care providers ask about?
The screening question needs to be specific. 'Do you use tobacco products?' will miss most pouch users because they do not consider pouches a tobacco product. 'Do you smoke or vape?' will miss them entirely. The question should be direct: 'Do you use nicotine pouches, Zyn, or any similar products?' Using brand names increases recognition and honest disclosure.
- Ask about nicotine pouches by name (Zyn, On!, Velo, Rogue) in addition to standard tobacco and vaping screening.
- Ask about frequency and dose: how many pouches per day and what milligram strength. A 15-year-old using ten 6 mg pouches daily has a very different exposure than one using two 3 mg pouches.
- Ask about timing relative to meals: using pouches on an empty stomach, first thing in the morning, or in rapid succession increases GI symptom risk.
- Ask about concurrent substances: energy drinks, caffeine, alcohol. These have additive GI effects with nicotine.
- Screen confidentially when possible. Teens are significantly more likely to disclose substance use when parents are not in the room.
đĄFor clinicians: consider adding nicotine pouches to your adolescent screening questionnaire alongside vaping and smoking. The 2024 AAP update on adolescent substance use screening recommends including oral nicotine products in the CRAFFT or similar screening tools.
Is the developing GI tract more vulnerable to nicotine?
This is an area with very limited data, and intellectual honesty requires saying so. Most of what we know about nicotine's GI effects comes from studies in adults, predominantly adult smokers. Whether the adolescent GI tract responds differently to nicotine has not been directly studied.
What we do know is that the GI system continues to mature through adolescence and into the mid-20s. The enteric nervous system (the gut's own nervous system, containing over 500 million neurons) undergoes refinement during this period. Gastric acid regulation, mucosal barrier function, and gut motility patterns are all still developing. A 2019 review by Rao and Gershon in Developmental Biology detailed the extended maturation timeline of the enteric nervous system.
The concern is not that nicotine will cause immediate, dramatic damage to the adolescent gut. It is that chronic nicotine exposure during a developmental window could affect the calibration of systems that regulate motility, sensitivity, and secretion. This is conceptually similar to the well-established concern about nicotine and the developing brain (which has much more data behind it). But for the gut, the concern remains theoretical. We simply do not have the long-term studies in young nicotine pouch users to know.
What does the clinical workup look like?
When a teen or young adult presents with nausea, heartburn, epigastric pain, or altered bowel habits, and nicotine pouch use is identified, the workup does not change dramatically. Standard evaluation for the presenting complaint is still appropriate. But the clinical context shifts.
For heartburn or suspected GERD: before starting a PPI, consider whether nicotine pouch use is the primary driver. A trial of pouch cessation or reduction (if the patient is willing) for 2 to 4 weeks is a reasonable first step before pharmacotherapy. If symptoms resolve, the diagnosis is essentially made without medication.
For unexplained nausea: correlate timing with pouch use. Nausea within 5 to 30 minutes of placing a pouch is strongly suggestive. Dose reduction (switching from 6 mg to 3 mg pouches) can be both diagnostic and therapeutic.
For altered bowel habits: nicotine's effect on gut motility is well established. If changes in stool frequency or urgency correlate with the onset of pouch use, the connection is likely. Standard red-flag screening (weight loss, blood in stool, family history of IBD) should still be performed.
What helps with identifying patterns in symptoms?
For both clinicians and young patients, having documented symptom patterns makes the clinical conversation more productive. Rather than relying on recall ('I think I felt sick a few times last week'), having a log of when symptoms occurred relative to pouch use, meals, and stress levels provides actionable data. Tools like GLP1Gut can help young users track their GI symptoms alongside daily habits so that both they and their providers can see the patterns clearly.
A note on approach: information, not fear
If you are a parent reading this, the instinct to panic is understandable. But scare tactics do not work well with teens, and exaggerating the risks of nicotine pouches undermines your credibility. The GI effects discussed here are real, but they are also generally reversible with dose reduction or cessation. Nicotine pouches are not going to destroy your teen's digestive system. They can, however, cause uncomfortable symptoms that your teen might not be connecting to their pouch use.
If you are a clinician, the same principle applies. A nonjudgmental, informational approach is more effective than a lecture. 'Nicotine pouches can cause the kind of nausea you are describing, and reducing your use is the easiest way to find out if that is what is going on' is more useful than a monologue about nicotine addiction. Meet the patient where they are.
If you are a teen or young adult reading this, and you are using pouches and having stomach issues: the connection is plausible and worth investigating. Try cutting your dose in half for two weeks and see what happens. You do not need anyone's permission to run that experiment on yourself.
Can nicotine pouches cause stomach ulcers in teens?
Nicotine increases gastric acid secretion, which is a risk factor for ulcer development, but nicotine pouches alone are unlikely to cause ulcers in otherwise healthy teens. Ulcers most commonly result from H. pylori infection or NSAID use. However, nicotine can worsen symptoms in someone who already has mucosal irritation.
Are lower-dose pouches (3 mg) safe for the stomach?
Lower doses produce fewer and milder GI effects than higher doses, but 'safe' is relative. A 3 mg pouch still delivers nicotine that relaxes the LES and stimulates acid secretion. Lower dose means lower risk of symptoms, not zero risk. The GI effects are dose-dependent, not threshold-dependent.
Should I take my teen to a GI specialist for pouch-related symptoms?
Start with primary care. If symptoms are mild and clearly correlate with pouch use, a trial of reduction or cessation is the most informative first step. A GI referral is appropriate if symptoms persist despite pouch cessation, if there are red-flag features (weight loss, blood in stool, severe pain), or if the diagnosis is uncertain.